Free Trial

Scancell (LON:SCLP) Stock Crosses Below Two Hundred Day Moving Average - What's Next?

Scancell logo with Medical background

Scancell Holdings plc (LON:SCLP - Get Free Report) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 10.35 ($0.14) and traded as low as GBX 9 ($0.12). Scancell shares last traded at GBX 9.20 ($0.12), with a volume of 119,982 shares traded.

Scancell Trading Down 0.5%

The company's fifty day simple moving average is GBX 9.28 and its two-hundred day simple moving average is GBX 10.35. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The company has a market capitalization of £95.29 million, a price-to-earnings ratio of -14.11 and a beta of 0.35.

Scancell Company Profile

(Get Free Report)

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Scancell Right Now?

Before you consider Scancell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.

While Scancell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

New AI Deals Just Sent These 4 Infrastructure Stocks Soaring
7 Nuclear Stocks One Announcement Away from Exploding
3 AI ETFs for Steady Gains in 2025 (Without the Wild Volatility)

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines